Ovid Therapeutics (OVID) Posts Q3 Loss, Falls Short of Revenue Projections
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 12 2025
0mins
Should l Buy TWST?
Source: NASDAQ.COM
Quarterly Performance: Ovid Therapeutics reported a quarterly loss of $0.17 per share, missing the Zacks Consensus Estimate of a loss of $0.15, and revenues of $0.13 million, which fell short of expectations by 61.18%.
Stock Movement and Outlook: The company's shares have increased by 44.6% since the beginning of the year, outperforming the S&P 500, but the future performance will depend on management's commentary and earnings estimate revisions.
Earnings Estimates: The current consensus EPS estimate for the upcoming quarter is -$0.09 on $0.24 million in revenues, while for the current fiscal year, it is -$0.44 on $6.82 million in revenues.
Industry Context: Ovid Therapeutics is part of the Medical - Biomedical and Genetics industry, which ranks in the top 34% of Zacks industries, indicating a potentially favorable environment for stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TWST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TWST
Wall Street analysts forecast TWST stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TWST is 41.25 USD with a low forecast of 39.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 47.100
Low
39.00
Averages
41.25
High
43.00
Current: 47.100
Low
39.00
Averages
41.25
High
43.00
About TWST
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Twist Bioscience Reports Strong Q1 Sales, Raises Guidance
- Strong Sales Performance: Twist Bioscience reported Q1 sales of $103.7 million, a 17% year-over-year increase, surpassing market expectations of $102.72 million, indicating robust market performance and growth potential.
- Stable Profitability Outlook: The company posted a loss of $0.50 per share, in line with Wall Street expectations, yet management remains focused on achieving profitability with gross margins above 50%, reflecting a healthy financial outlook.
- Raised Sales Guidance: Twist Bioscience increased its fiscal 2026 sales guidance from $425 million-$435 million to $435 million-$440 million, exceeding the consensus of $431.39 million, demonstrating confidence in future growth.
- Analyst Rating Upgrades: Barclays analyst raised the price target from $39 to $50, while Evercore ISI analyst increased the target from $42 to $52, reflecting optimistic market sentiment regarding Twist Bioscience's future performance.
See More
Twist Bioscience Reports Q1 2026 Results with Revenue Growth and Improved Margins
- Earnings Meet Expectations: Twist Bioscience reported a Q1 2026 loss of $0.50 per share, aligning with Wall Street forecasts, while sales reached $103.7 million, a 17% year-over-year increase that surpassed the consensus of $102.72 million, indicating strong market competitiveness and growth potential.
- Customer Base Expansion: The company shipped products to approximately 2,538 customers in Q1, up from about 2,376 a year ago, demonstrating ongoing progress in customer acquisition and market penetration.
- Gene Shipment Growth: Twist shipped approximately 271,000 genes this quarter, significantly up from 205,000 a year prior, with over 50,000 genes manufactured for data characterization, reflecting robust demand in the gene synthesis sector.
- Sales Guidance Raised: The company raised its fiscal 2026 sales guidance from $425 million-$435 million to $435 million-$440 million, with expected Q2 sales between $107 million-$108 million, showcasing confidence in future performance and optimistic market outlook.
See More
Twist Bioscience Reports Strong Q1 2026 Earnings with Revenue Growth
- Consistent Growth: Twist Bioscience reported Q1 2026 revenue of $103.7 million, a 17% year-over-year increase, marking the 12th consecutive quarter of revenue growth, demonstrating strong performance in the life sciences tools sector.
- Margin Improvement: The gross margin for Q1 reached 52.0%, up 4 percentage points from the previous year, reflecting the company's success in managing operating expenses, which totaled $86.9 million.
- Optimistic Outlook: The company expects total revenue for fiscal 2026 to be between $435 million and $440 million, with a growth rate of approximately 16%, and reiterated its goal of achieving adjusted EBITDA breakeven in Q4 2026.
- AI-Driven Growth: The company secured over $25 million in orders in the AI-enabled discovery market, projecting a potential addressable market of over $12 billion by 2030, indicating strong market potential and strategic direction.
See More
Twist Bioscience Raises FY 2026 Revenue Guidance
- Revenue Guidance Raised: Twist Bioscience has raised its FY 2026 total revenue guidance to between $435 million and $440 million, exceeding the analyst estimate of $430.84 million, indicating strong market performance.
- Significant Quarterly Growth: The company expects Q2 revenue to be approximately $107 million to $108 million, marking a year-over-year growth of about 16%, which not only surpasses the estimated $105.08 million but also reflects a growing customer base.
- EBITDA Breakeven Target: Twist anticipates achieving adjusted EBITDA breakeven in Q4 of FY 2026, which will further bolster investor confidence and improve financial health.
- Strong Q1 Performance: For Q1, total revenue reached $103.7 million, a 17% increase that exceeded the expected $100.33 million, with the customer count rising from 2,376 to 2,538, demonstrating robust product demand.
See More
Twist Bioscience Reports Improved Q1 Losses, Shares Rise
- Financial Performance: Twist Bioscience's Q1 report shows a reduced loss of $30.5 million, or $0.50 per share, compared to last year's loss of $31.6 million, or $0.53 per share, indicating an improvement in financial health.
- Revenue Growth: The company reported Q1 revenue of $103.7 million, up 16.8% from $88.7 million in the same period last year, reflecting strong market demand and sales performance.
- Stock Price Surge: Following the positive earnings report, Twist Bioscience shares rose approximately 7% in Nasdaq trading, currently priced at $44.23, up $3.28 from the previous close of $41.07, showcasing investor optimism about the company's outlook.
- Annual Volatility: Over the past year, Twist Bioscience's stock has fluctuated between $23.30 and $54.74, indicating a mix of high investor interest and uncertainty regarding its future growth potential.
See More
Twist Bioscience Raises FY26 Revenue Guidance Despite Mixed Q1 Results
- Revenue Guidance Increase: Twist Bioscience raised its FY26 revenue forecast from $425M-$435M to $435M-$440M, exceeding the market consensus of $431.67M, indicating strong confidence in future growth.
- Q2 Outlook: The company projects FY26 Q2 revenue between $107M and $108M, also above the consensus of $104.36M, suggesting sustained competitiveness in the market.
- Q1 Financial Results: Despite a non-GAAP EPS loss of -$0.50 in Q1, an improvement from -$0.53 year-over-year, the revenue of $103.7M fell short of expectations, highlighting challenges in revenue growth.
- Cash Position: As of the end of 2025, Twist Bioscience reported $198M in cash and short-term investments, down from $232.4M on September 30, 2025, reflecting pressure on the company's financial management.
See More
Twist Bioscience Reports Strong Q1 Sales, Raises Guidance
- Strong Sales Performance: Twist Bioscience reported Q1 sales of $103.7 million, a 17% year-over-year increase, surpassing market expectations of $102.72 million, indicating robust market performance and growth potential.
- Stable Profitability Outlook: The company posted a loss of $0.50 per share, in line with Wall Street expectations, yet management remains focused on achieving profitability with gross margins above 50%, reflecting a healthy financial outlook.
- Raised Sales Guidance: Twist Bioscience increased its fiscal 2026 sales guidance from $425 million-$435 million to $435 million-$440 million, exceeding the consensus of $431.39 million, demonstrating confidence in future growth.
- Analyst Rating Upgrades: Barclays analyst raised the price target from $39 to $50, while Evercore ISI analyst increased the target from $42 to $52, reflecting optimistic market sentiment regarding Twist Bioscience's future performance.
See More
Twist Bioscience Reports Q1 2026 Results with Revenue Growth and Improved Margins
- Earnings Meet Expectations: Twist Bioscience reported a Q1 2026 loss of $0.50 per share, aligning with Wall Street forecasts, while sales reached $103.7 million, a 17% year-over-year increase that surpassed the consensus of $102.72 million, indicating strong market competitiveness and growth potential.
- Customer Base Expansion: The company shipped products to approximately 2,538 customers in Q1, up from about 2,376 a year ago, demonstrating ongoing progress in customer acquisition and market penetration.
- Gene Shipment Growth: Twist shipped approximately 271,000 genes this quarter, significantly up from 205,000 a year prior, with over 50,000 genes manufactured for data characterization, reflecting robust demand in the gene synthesis sector.
- Sales Guidance Raised: The company raised its fiscal 2026 sales guidance from $425 million-$435 million to $435 million-$440 million, with expected Q2 sales between $107 million-$108 million, showcasing confidence in future performance and optimistic market outlook.
See More
Twist Bioscience Reports Strong Q1 2026 Earnings with Revenue Growth
- Consistent Growth: Twist Bioscience reported Q1 2026 revenue of $103.7 million, a 17% year-over-year increase, marking the 12th consecutive quarter of revenue growth, demonstrating strong performance in the life sciences tools sector.
- Margin Improvement: The gross margin for Q1 reached 52.0%, up 4 percentage points from the previous year, reflecting the company's success in managing operating expenses, which totaled $86.9 million.
- Optimistic Outlook: The company expects total revenue for fiscal 2026 to be between $435 million and $440 million, with a growth rate of approximately 16%, and reiterated its goal of achieving adjusted EBITDA breakeven in Q4 2026.
- AI-Driven Growth: The company secured over $25 million in orders in the AI-enabled discovery market, projecting a potential addressable market of over $12 billion by 2030, indicating strong market potential and strategic direction.
See More
Twist Bioscience Raises FY 2026 Revenue Guidance
- Revenue Guidance Raised: Twist Bioscience has raised its FY 2026 total revenue guidance to between $435 million and $440 million, exceeding the analyst estimate of $430.84 million, indicating strong market performance.
- Significant Quarterly Growth: The company expects Q2 revenue to be approximately $107 million to $108 million, marking a year-over-year growth of about 16%, which not only surpasses the estimated $105.08 million but also reflects a growing customer base.
- EBITDA Breakeven Target: Twist anticipates achieving adjusted EBITDA breakeven in Q4 of FY 2026, which will further bolster investor confidence and improve financial health.
- Strong Q1 Performance: For Q1, total revenue reached $103.7 million, a 17% increase that exceeded the expected $100.33 million, with the customer count rising from 2,376 to 2,538, demonstrating robust product demand.
See More
Twist Bioscience Reports Improved Q1 Losses, Shares Rise
- Financial Performance: Twist Bioscience's Q1 report shows a reduced loss of $30.5 million, or $0.50 per share, compared to last year's loss of $31.6 million, or $0.53 per share, indicating an improvement in financial health.
- Revenue Growth: The company reported Q1 revenue of $103.7 million, up 16.8% from $88.7 million in the same period last year, reflecting strong market demand and sales performance.
- Stock Price Surge: Following the positive earnings report, Twist Bioscience shares rose approximately 7% in Nasdaq trading, currently priced at $44.23, up $3.28 from the previous close of $41.07, showcasing investor optimism about the company's outlook.
- Annual Volatility: Over the past year, Twist Bioscience's stock has fluctuated between $23.30 and $54.74, indicating a mix of high investor interest and uncertainty regarding its future growth potential.
See More
Twist Bioscience Raises FY26 Revenue Guidance Despite Mixed Q1 Results
- Revenue Guidance Increase: Twist Bioscience raised its FY26 revenue forecast from $425M-$435M to $435M-$440M, exceeding the market consensus of $431.67M, indicating strong confidence in future growth.
- Q2 Outlook: The company projects FY26 Q2 revenue between $107M and $108M, also above the consensus of $104.36M, suggesting sustained competitiveness in the market.
- Q1 Financial Results: Despite a non-GAAP EPS loss of -$0.50 in Q1, an improvement from -$0.53 year-over-year, the revenue of $103.7M fell short of expectations, highlighting challenges in revenue growth.
- Cash Position: As of the end of 2025, Twist Bioscience reported $198M in cash and short-term investments, down from $232.4M on September 30, 2025, reflecting pressure on the company's financial management.
See More
